查看文章

Objective  To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts.

Design  Cost‐utility analysis.

Setting  UK.

Population  Female and male UK population 12 years or older.

Methods  We adapted a previously developed multi‐HPV type dynamic transmission to compare four female vaccination strategies, routine vaccination at age 12 years, and routine vaccination at age 12 years combined with temporary catch‐up vaccination at ages 12–14, 12–17 and 12–24 years.

Main outcomes measures  Costs, cases avoided, incremental cost per quality‐adjusted life year (QALY).

Results  The model projected that at year 100, each vaccination strategy could reduce the number of HPV 6/11/16/18‐related cervical cancer …